• Similar to BioMarin Pharmaceutical, but specializing in therapies for rare genetic diseases that cause severe obesity.
• A Vertex Pharmaceuticals focused on developing specialized treatments for rare genetic forms of obesity.

• Imcivree (setmelanotide): A melanocortin-4 (MC4) receptor agonist approved for the treatment of obesity and hyperphagia caused by specific rare genetic disorders.

Rhythm Pharmaceuticals (RYTM) primarily sells its products to other companies, specifically major pharmaceutical wholesale distributors.

Its major customers, which accounted for substantially all of its net product revenue in recent years, are:

• McKesson Corporation (Symbol: MCK)
• Cardinal Health, Inc. (Symbol: CAH)
• AmerisourceBergen Corporation (Symbol: ABC)

• Lonza Ltd. (LONN.SW)
• Catalent, Inc. (CTLT)

David Meeker, MD Chairman, President, and Chief Executive Officer

David Meeker was appointed President and Chief Executive Officer of Rhythm Pharmaceuticals in July 2020, having served as Chairman of the Board since 2017 and a board member since 2015. Before joining Rhythm, he spent approximately three years as President and CEO of KSQ Therapeutics. Prior to that, he was the Executive Vice President and Head of Sanofi Genzyme, where he advanced from Medical Director in 1994 to Chief Operating Officer and Chief Executive Officer. At Genzyme, he led the commercial organization and global market access functions, overseeing the launch of several treatments for rare genetic diseases, including Aldurazyme®, Fabrazyme®, and Myozyme®. He also serves as Chairman of the board for Trevi Therapeutics and Pharvaris.

Hunter Smith Chief Financial Officer

Hunter Smith has served as Chief Financial Officer of Rhythm Pharmaceuticals since August 2017 and held the role of interim Chief Executive Officer from March to July 2020. During his tenure, he has been instrumental in leading the company through its initial public offering and subsequent capital raises, securing over $1 billion. Before joining Rhythm, he was the Vice President, Finance and Chief Financial Officer of the Inflammation and Immunology Business Unit at Celgene Corporation, where he provided finance leadership for the global launch of Otezla® and co-led the integration of Receptos, Inc. following its acquisition. He also spent fourteen years at Bunge Limited, holding various leadership positions including Director of Investor Relations, Chief Financial Officer–Asia, Chief Risk Officer, Corporate Treasurer, and Chief Financial Officer of Bunge's Sugar and Bioenergy Segment. Smith previously served as an Independent Director of Genessee & Wyoming Inc. until its acquisition in December 2019, and on the Board of Directors of Aeglea BioTherapeutics Inc. through its merger with Spyre Therapeutics.

Yann Mazabraud Executive Vice President, Head of International

Yann Mazabraud joined Rhythm Pharmaceuticals in October 2020, bringing more than two decades of experience in leading rare disease global commercial strategy, market access, and marketing. Prior to Rhythm, he served as Chief Commercial Officer and Head of International at Trevi Therapeutics for two years. He also held several leadership positions at Sanofi Genzyme, including Head of Latin America, U.S. General Manager, and North America Head, Rare Diseases, and was a member of the Sanofi Genzyme Executive Leadership Team.

Jennifer Lee Executive Vice President North America

Jennifer Lee became Rhythm Pharmaceuticals' Executive Vice President North America in November 2020. She has over 20 years of experience in strategy and commercialization within the rare diseases sector. Most recently, she was the Chief Commercial Officer at Krystal Biotech. Before that, she served as Vice President, Head of Genetic Diseases at Sanofi Genzyme, where she was responsible for the U.S. commercial strategy and implementation of seven brands, as well as launch preparation in rare diseases.

Murray Stewart, MD Chief Medical Officer

Murray Stewart joined Rhythm Pharmaceuticals as Chief Medical Officer in October 2018. His previous roles include Head of R&D for Novelion, where he oversaw global medical affairs for Juxtapid® and Myalept®, products for rare metabolic diseases. Before Novelion, he was Chief Medical Officer at GlaxoSmithKline (GSK), with global responsibility for patient well-being across their vaccine, pharmaceutical, and consumer business units. During his 18 years at GSK, he held multiple R&D leadership roles, including Chief Medical Officer for the pharmaceutical business and Therapy Area Head for metabolic and cardiovascular diseases. He also serves as a board director for X4 Pharmaceuticals and Camp4.

Rhythm Pharmaceuticals' main product, IMCIVREE (setmelanotide), addresses several rare genetic disorders of obesity.

• Bardet-Biedl Syndrome (BBS): The addressable market for BBS in the U.S. is approximately 1,500-2,500 people.
• Pro-opiomelanocortin (POMC) Deficiency, Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) Deficiency, and Leptin Receptor (LEPR) Deficiency: IMCIVREE is approved for these rare genetic disorders in the U.S., Europe, and the UK. Specific addressable market sizes for these individual deficiencies were not identified in the provided information.

Rhythm Pharmaceuticals is also developing IMCIVREE for additional indications:

• Acquired Hypothalamic Obesity (HO): The addressable market in the U.S. affects approximately 10,000–15,000 patients.
• Prader-Willi Syndrome (PWS): The global patient population is estimated at 400,000 individuals, with 20,000 individuals in the United States. The global market for Prader-Willi syndrome is anticipated to exceed USD 1,131.94 million by 2033. The market size across the 7MM (United States, EU5, and Japan) was USD 834 million in 2022.

Rhythm Pharmaceuticals (RYTM) is expected to drive future revenue growth over the next 2-3 years through several key strategies focused on expanding its lead asset, IMCIVREE (setmelanotide), and advancing its pipeline.

• Expansion into Acquired Hypothalamic Obesity (HO): A significant driver is the potential label expansion for IMCIVREE to treat acquired hypothalamic obesity. The U.S. FDA has extended its review period for the supplemental New Drug Application (sNDA), with a new Prescription Drug User Fee Act (PDUFA) goal date of March 20, 2026. This represents a substantial new market for IMCIVREE, with the company remaining confident in the drug's potential.
• Growth in Existing IMCIVREE Indications: Continued growth in the number of reimbursed patients for IMCIVREE's currently approved indications, such as Bardet-Biedl syndrome (BBS) and pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiency obesities, is a consistent revenue driver. Global sales of IMCIVREE have shown strong year-over-year increases, with a notable boost from U.S. sales.
• Advancement in Prader-Willi Syndrome: Rhythm Pharmaceuticals is on track to report preliminary results from its Phase 2 trial of setmelanotide in Prader-Willi syndrome in the fourth quarter of 2025. Positive trial results could lead to further clinical development and eventual regulatory approval, opening another significant patient population for IMCIVREE.
• Pipeline Development of New MC4R Agonists: The company is advancing investigational melanocortin-4 receptor (MC4R) agonists, including bivamelagon and RM-718, for other rare diseases, particularly acquired hypothalamic obesity. A Phase 2 trial for bivamelagon met its primary endpoint in acquired hypothalamic obesity, with a Phase 3 study planned for the next year. These programs represent future product launches and diversification of the revenue stream.
• International Market Expansion for IMCIVREE: Rhythm Pharmaceuticals continues to expand its international presence for IMCIVREE, operating in over 15 countries. Public reimbursement for IMCIVREE in Canada across multiple provinces and under federal programs was announced in November 2025, indicating ongoing efforts to broaden geographical reach and patient access.

Share Issuance

• In July 2025, Rhythm Pharmaceuticals priced an upsized public offering of 2,058,824 shares at $85.00 per share, expecting to generate approximately $175 million in gross proceeds.
• The company closed this offering on July 11, 2025, with 2,367,647 shares of common stock at $85 per share, resulting in net proceeds of approximately $189.2 million.
• In April 2024, Rhythm secured $150 million in gross proceeds from the sale of Series A convertible preferred stock to current shareholders, including Perceptive Advisors LLC and its Discovery Fund.

Inbound Investments

• Rhythm Pharmaceuticals entered into a Revenue Interest Financing Agreement with HealthCare Royalty Partners in June 2022 for up to $100 million, of which $96.7 million had been received as of September 30, 2024.
• The $150 million in convertible preferred stock financing obtained in April 2024 is intended to fund clinical development programs, commercialization activities, working capital, and general corporate purposes.

Outbound Investments

• In March 2025, Rhythm reacquired the rights to its product IMCIVREE in China, encompassing mainland China, Hong Kong, and Macau, by terminating a 2021 licensing agreement with RareStone Group Ltd.

Capital Expenditures

• As of September 30, 2025, Rhythm expects its existing cash, cash equivalents, and short-term investments to be sufficient to fund its operating expenses and capital expenditure requirements for at least 24 months.
• The company's cash runway is anticipated to extend into 2027, covering current clinical trials and preparations for the launch of its hypothalamic obesity (HO) program.
• This projected runway excludes new clinical development work and investments in Chemistry, Manufacturing, and Controls (CMC) for future planning success.